GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Invion Ltd (FRA:7C8) » Definitions » Net Current Asset Value

Invion (FRA:7C8) Net Current Asset Value : €0.01 (As of Jun. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Invion Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Invion's net current asset value per share for the quarter that ended in Jun. 2024 was €0.01.

The historical rank and industry rank for Invion's Net Current Asset Value or its related term are showing as below:

FRA:7C8' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 5   Med: 50   Max: 340
Current: 14.6

During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Invion was 340.00. The lowest was 5.00. And the median was 50.00.

FRA:7C8's Price-to-Net-Current-Asset-Value is ranked worse than
75.78% of 611 companies
in the Drug Manufacturers industry
Industry Median: 5.81 vs FRA:7C8: 14.60

Invion Net Current Asset Value Historical Data

The historical data trend for Invion's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invion Net Current Asset Value Chart

Invion Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 - 0.08 0.05 0.01

Invion Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.08 0.05 0.04 0.01

Competitive Comparison of Invion's Net Current Asset Value

For the Drug Manufacturers - Specialty & Generic subindustry, Invion's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Invion's Price-to-Net-Current-Asset-Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Invion's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Invion's Price-to-Net-Current-Asset-Value falls into.



Invion Net Current Asset Value Calculation

Invion's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Jun. 2024 is calculated as

Net Current Asset Value Per Share(A: Jun. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1.284-0.626-0-0)/66.0453
=0.01

Invion's Net Current Asset Value (NCAV) per share for the quarter that ended in Jun. 2024 is calculated as

Net Current Asset Value Per Share(Q: Jun. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1.284-0.626-0-0)/66.0453
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Invion  (FRA:7C8) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Invion Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Invion's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Invion Business Description

Traded in Other Exchanges
Address
692 High Street, East Kew, VIC, AUS, 3102
Invion Ltd is an Australian clinical-stage pharmaceutical drug development company. It is engaged in the development of PhotoDynamic Therapy (PDT) for cancer treatments. The company produces topical and intravenous products suitable for use in skin cancer and solid tumors, such as ovarian, prostate, and lung cancer.

Invion Headlines

No Headlines